Ozempic Was Never a Weight-Loss Drug. The Internet Made It One.

Somewhere in late 2022, a clip surfaced of a slimmed-down celebrity, a knowing aside about a once-weekly injection, and a comment section that did the rest. Within weeks the word was everywhere — on red carpets, in office Slack channels, whispered across dinner tables: Ozempic. It became a verb, a punchline, a status symbol, and a moral panic, all at once. There was just one problem with the entire conversation. The drug everyone was talking about as a weight-loss miracle had never been approved to make anyone lose weight.

The official story is that Novo Nordisk launched a wonder drug for obesity and the world swooned. Almost none of that is right. Ozempic was approved on December 5, 2017 for one thing: type 2 diabetes.¹ The cultural phenomenon was not a product launch. It was an accident the company never planned, could not have planned, and at first could not even supply.

Two drugs, one molecule, and the wrong one got famous

Here is the part that almost everyone gets backwards. Semaglutide — the active molecule — is sold under more than one name. As Ozempic, dosed for blood sugar, it has been a diabetes drug since 2017.¹ As Wegovy, the same molecule at a higher 2.4 mg dose, it was approved specifically for chronic weight management on June 4, 2021.² So there was a sanctioned weight-loss product. The strange thing is that fame skipped right past it. The name that detonated across the internet was the diabetes brand, prescribed off-label by doctors and demanded by patients who had no diabetes at all. Novo Nordisk, for its part, has publicly stated it does not support off-label use of its medicines — which is the corporate way of saying the most valuable marketing event in its history was one it could not endorse.

The fuse was lit by celebrities, not a campaign

If the phenomenon had been engineered, the timing would track the science. It doesn't. Wegovy — the actual weight-loss drug — was approved in June 2021, and for roughly eighteen months almost nothing happened culturally. The real inflection point sits in the last quarter of 2022, when social-media promotion of Ozempic took off. A Wayne State analysis of Medicaid data found that exact window: a Q4 2022 surge in social promotion, followed by Ozempic becoming harder for the diabetic patients it was designed for to obtain.³ The lag is the tell. A regulatory event in 2021 did not start this. Celebrity disclosure and viral video in 2022 did — eighteen months and a TikTok feed apart.

And the reason that virality could run unchecked is itself a structural gap, not a coincidence. The FDA's guidance on social-media drug marketing was last meaningfully updated in 2014 — before TikTok existed.⁸ So the disclosure rules that govern a glossy pharma ad simply do not reach an unpaid, off-the-cuff celebrity mention. The most powerful drug promotion of the decade was technically not drug promotion at all. It lived in the one place the rulebook never anticipated, and it spread the way nothing in a regulated launch ever could: for free, with no fine print, and no one accountable for the claim.

The demand the forecast never saw coming

Manufacturing a complex injectable is planned years out, against a forecast of how many diabetics will need it. No model in that planning cycle contained a line item for 'the entire internet decides this is the secret to thinness.' So the math broke. The FDA declared an official shortage of Ozempic and Wegovy in August 2022 — before the craze even peaked — and the gap between what people wanted and what existed opened a side door.⁶ Into it walked the compounders: pharmacies legally permitted to mix their own semaglutide during a shortage. By January 2026, Novo Nordisk's own CEO put the count at up to 1.5 million users of compounded GLP-1 drugs in the US.⁶ A phenomenon the company never started had spawned a parallel supply it didn't control and couldn't bill for.

What the accident built, though, was staggering. In 2023 Ozempic alone generated roughly $13.9 billion in sales — more than double Wegovy's $6.0 billion — because the diabetes indication carries far broader insurance coverage and a longer market history.⁵ Together the two drugs cleared about $18.4 billion and accounted for over 60% of Novo Nordisk's total revenue.⁵ Read that twice: a single molecule, made famous off-label by people the company couldn't pay or control, came to define the entire enterprise.

The same story, played backwards

Here is the structural risk hiding inside the success, and it is the cultural narrative running in reverse. The popular story is transformation — a permanent before-and-after. The clinical data tells a colder one. In the STEP 1 trial extension, participants lost a mean 17.3% of body weight on semaglutide; one year after stopping, they had regained two-thirds of it, settling at a net 5.6% loss, with most cardiometabolic gains drifting back toward baseline.⁴ This is not a cure. It is a tap. Turn it off, and the body returns. Which means the real product was never a transformation — it was a subscription. Permanent dependency is the business model. It is also, precisely, the line the backlash forms along: a drug you must take forever to keep a result you were sold as a one-time fix.

But isn't the medicine simply that good?

The fair objection is that none of this matters if the drug works — and on the evidence, it does far more than slim faces for a camera. In a trial of more than 17,600 participants, Wegovy cut the risk of major adverse cardiovascular events — cardiovascular death, heart attack, stroke — from 8% on placebo to 6.5%, earning an FDA cardiovascular-risk indication in March 2024 and becoming the first weight-loss medicine also approved to protect the heart.⁷ That is real, hard clinical value, not a viral illusion. The honest counter holds anyway. A drug being genuinely effective is exactly what makes the chronic-dependency problem sharper, not softer: stop it and the cardiometabolic benefits fade with the weight.⁴ The medicine is the asset and the liability at once. Its power is inseparable from the fact that you can never put it down — and a phenomenon built on the promise of an ending is most fragile precisely where the science says there isn't one.

Novo Nordisk did not make Ozempic a cultural icon. The internet did, by misreading a diabetes drug as a thinness machine and demanding it by the millions through doors no one had built. The company inherited a phenomenon and a fortune it never designed — and inside both sits the same uncomfortable fact the clinical data keeps repeating: this works only as long as you never stop. The drug that became a movement built its empire on a promise the science quietly refuses to make. Stop the shot, and most of the story comes back.